Cardiovascular disease Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
16:01
Jan 08
Jan 08
Obesity, cardiovascular attractive for M&A.
Cardio-metabolic/obesity and cardiovascular disease are key M&A areas for large pharma; Pfizer and Novo Nordisk's bidding war for a monthly GLP-1 injection and cardiovascular disease being part of a recent transaction show strong appetite.
MED
About Cardiovascular disease Investor Commentary
Across the available history and selected sources, Buzzberg tracks Cardiovascular disease across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Michael Yee.